Answers are grounded in this paper and cite their sources.
To the Editor: CD34, the human progenitor-cell antigen, is a marker of a subpopulation of dermal spindle cells located in the dermis termed dermal dendritic cells (DDCs). CD34+ DDCs are predominantly located in the reticular and periadnexal dermis. Studies have suggested that they are involved in antigen presentation and maintenance of dermal architecture.1,2 CD34+ DDCs are implicated in several pathologic processes. In nephrogenic systemic fibrosis, CD34+ DDCs are floridly increased in number. It is believed that gadolinium triggers the activation of CD34+ DDCs to release cytokines that in turn induce the accumulation and activation of fibroblasts and hematopoietic progenitor cells.3 CD34+ DDCs are the probable cell for origin of dermatofibrosarcoma protuberans and are increased in several benign dermal stromal tumors. The dermal sclerosis in morphea is characterized by a reduction or complete loss of CD34+ DDCs.1,2,4 CD34 staining is a well-recognized and frequently used diagnostic adjunct in difficult cases. Other connective tissue diseases (systemic lupus erythematosus, discoid lupus erythematosus, and dermatomyositis) do not result in a similar complete loss of CD34 staining.1 The status of CD34+ DDCs has not been reported in disorders of collagen alteration other than morphea and scleroderma. We assessed cases of lichen sclerosus (LS), as this condition is characterized by homogenized collagen and cases of granuloma annulare (GA) and necrobiosis lipoidica (NL), which are characterized by granulomas with “necrobiotic” or degenerated collagen. Cases were identified at a single laboratory in Vancouver, Canada. Hematoxylin-and-eosin (H&E)–stained paraffin-embedded sections of LS (n = 5), GA (n = 5), and NL (n = 3) were reviewed to confirm the diagnosis and identify the areas of altered collagen. Immunohistochemical staining for CD34 (Dako Omnis, Santa Barbara, CA) was undertaken on 6-μm sections. The staining intensity was graded as absent, reduced, or normal. The unaffected areas of the dermis acted as an internal positive control. CD34 expression was completely lost in all areas of affected collagen visible on H&E in all of our cases of LS and GA (Figs. 1A–D). All areas that appeared normal on H&E had an expected level of CD34 expression. In NL, some areas that had morphologically unaltered collagen showed complete loss of CD34 staining (Figs. 1E, F). Conversely, some areas of degenerating collagen showed reduction rather than complete loss of CD34 expression. In all cases, immunoreactivity was retained as expected in endothelial cells.FIGURE 1.: Representative images of H&E and CD34 stained slides from biopsies of patients with GA, LS, and NL at 100×. A, (H&E) and (B) (CD34) depict a case of GA showing complete loss of CD34+ DDCs in the areas of altered collagen. C, (H&E) and (D) (CD34) depict a case of LS showing complete loss of CD34+ DDCs in the areas of altered collagen. E, (H&E) and (F) (CD34) depict a case of NL showing complete loss of CD34+ DDCs both in areas of altered collagen and in areas of morphologically normal collagen.In morphea, a phenotypic change of CD34+ DDCs into smooth-muscle actin+ myofibroblasts has been proposed.4 The complete loss of CD34+ DDCs in areas of dermal alteration in LS and GA may be useful in confirming the diagnosis in early lesions or nonrepresentative biopsies. CD34 staining may be particularly useful for the early detection of NL, as areas that were not detectably abnormal on H&E were found to have complete loss of CD34 expression. Our findings indicate that CD34 staining will not be useful in distinguishing LS from superficial morphea. Our findings suggest areas for future investigation. Early lesions of LS are difficult to differentiate from other lichenoid dermatoses such as lichen planus. All of our cases of LS in this study were established lesions; however, a future study examining early lesions may determine if CD34 is useful in this differential diagnosis. Additionally, all of our cases were classic palisading GA; a future study could examine interstitial GA, where the collagen alteration is more subtle and the diagnosis more challenging. In conclusion, CD34 staining is lost not only in morphea but also in other disorders of collagen degeneration, and it may be a useful diagnostic adjunct in these conditions as well, particularly in early evolving disease or nonrepresentative biopsies.
No takes yet. Share an insight, caveat, or question.
Borretta et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: